Related Experiment Video
Updated: May 24, 2026
12:45
Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
Published on: February 12, 2022
Transanal endoscopic microsurgery: a Brazilian initial experience in private practice.
Sergio Eduardo Alonso Araujo1, Victor Edmond Seid, Lucas de Araujo Horcel
1Colorectal Surgery Division, Sao Camilo Medical Center, Sao Paulo, Brazil. sergioaraujo@colorretal.com.br
Hepato-Gastroenterology
|March 6, 2012
Summary
Transanal endoscopic microsurgery (TEM) offers a minimally invasive option for rectal lesions, demonstrating low morbidity and curative potential for early cancers in initial institutional experience.
Area of Science:
- Colorectal Surgery
- Minimally Invasive Procedures
- Oncology
Background:
- Transanal endoscopic microsurgery (TEM) provides superior rectal exposure compared to conventional transanal excision.
- This approach potentially reduces the risk of compromised margins and lowers recurrence rates for rectal lesions.
Purpose of the Study:
- To describe a single institution's initial experience with transanal endoscopic microsurgery (TEM).
- To evaluate the safety and efficacy of TEM for various rectal lesions.
Main Methods:
- Retrospective review of a prospective database.
- Analysis of 50 transanal endoscopic microsurgery (TEM) procedures performed between March 2009 and November 2011.
Main Results:
- The mean operating time was 110 minutes with a 16% postoperative complication rate and no mortality.
- Pathology included adenoma (25), in situ adenocarcinoma (8), invasive adenocarcinoma (13), and neuroendocrine carcinoma (3).
- Recurrence rates were 4% for benign and 8% for malignant tumors after a mean follow-up of 23 months.
Conclusions:
- Transanal endoscopic microsurgery (TEM) is a minimally invasive procedure with low postoperative morbidity.
- TEM is curative for benign lesions and selected early-stage rectal cancers.
- TEM may be beneficial for selected cancers after neoadjuvant therapy, pending multi-institutional trial results.
